Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance.

Papadopoulos EI, Papachristopoulou G, Ardavanis A, Scorilas A.

Clin Biochem. 2018 Jul 29. pii: S0009-9120(18)30339-4. doi: 10.1016/j.clinbiochem.2018.07.008. [Epub ahead of print]

PMID:
30063890
2.

Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.

Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, Ardavanis A.

In Vivo. 2018 May-Jun;32(3):653-657.

3.

Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.

Haritos C, Michaelidou K, Mavridis K, Missitzis I, Ardavanis A, Griniatsos J, Scorilas A.

Clin Exp Med. 2018 May;18(2):203-213. doi: 10.1007/s10238-018-0487-4. Epub 2018 Feb 12.

PMID:
29435805
4.

Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.

Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN.

J Immunother Cancer. 2017 May 30;5:48. doi: 10.1186/s40425-017-0248-z. eCollection 2017.

5.

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.

Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN.

J Immunother Cancer. 2017 Apr 18;5:39. doi: 10.1186/s40425-017-0240-7. eCollection 2017. Erratum in: J Immunother Cancer. 2017 May 30;5:48.

6.

Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.

Stefanou D, Stamatopoulou S, Sakellaropoulou A, Akakios G, Gkiaouraki M, Gkeka D, Prevezanou M, Ardavanis A.

Oncol Lett. 2016 Dec;12(6):4635-4642. doi: 10.3892/ol.2016.5268. Epub 2016 Oct 17.

7.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE.

Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751.

8.

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).

Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A; HORG’s Lung Cancer Working Group.

Cancer Chemother Pharmacol. 2016 Aug;78(2):369-76. doi: 10.1007/s00280-016-3094-7. Epub 2016 Jun 22.

PMID:
27335027
9.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.

Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30.

10.

Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.

Michaelidou K, Ardavanis A, Scorilas A.

Breast Cancer Res Treat. 2015 Jul;152(2):323-36. doi: 10.1007/s10549-015-3470-8. Epub 2015 Jun 24.

PMID:
26099606
11.

Are Thyroid Hormone and Tumor Cell Proliferation in Human Breast Cancers Positive for HER2 Associated?

Mourouzis I, Tzovaras A, Armonis B, Ardavanis A, Skondra M, Misitzis J, Pectasides D, Pantos C.

Int J Endocrinol. 2015;2015:765406. doi: 10.1155/2015/765406. Epub 2015 Jan 28.

12.

BCL2L12: a promising molecular prognostic biomarker in breast cancer.

Tzovaras A, Kladi-Skandali A, Michaelidou K, Zografos GC, Missitzis I, Ardavanis A, Scorilas A.

Clin Biochem. 2014 Dec;47(18):257-62. doi: 10.1016/j.clinbiochem.2014.09.008. Epub 2014 Sep 16.

PMID:
25230343
13.

Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.

Florou D, Patsis C, Ardavanis A, Scorilas A.

Cancer Biol Ther. 2013 Jul;14(7):587-96. doi: 10.4161/cbt.24591. Epub 2013 May 10.

14.

The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression.

Michaelidou K, Tzovaras A, Missitzis I, Ardavanis A, Scorilas A.

Int J Oncol. 2013 May;42(5):1770-7. doi: 10.3892/ijo.2013.1860. Epub 2013 Mar 21.

PMID:
23525470
15.

Breakthrough cancer pain: an observational study of 1000 European oncology patients.

Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, Slama O, Korhonen T, Filbet M, Poulain P, Mystakidou K, Ardavanis A, O'Brien T, Wilkinson P, Caraceni A, Zucco F, Zuurmond W, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L, Sjolund KF, Stenberg M.

J Pain Symptom Manage. 2013 Nov;46(5):619-28. doi: 10.1016/j.jpainsymman.2012.12.009. Epub 2013 Mar 22.

PMID:
23523361
16.

The C-terminal decapeptide of prothymosin α is responsible for its stimulatory effect on the functions of human neutrophils in vitro.

Samara P, Ioannou K, Neagu M, Arnogiannaki N, Ardavanis A, Voelter W, Tsitsilonis O.

Int Immunopharmacol. 2013 Jan;15(1):50-7. doi: 10.1016/j.intimp.2012.11.011. Epub 2012 Nov 29.

PMID:
23201434
17.

Bevacizumab therapy may contribute to irradiation deferral in patients with breast cancer and with central nervous system metastases: findings of a case series.

Kountourakis P, Dokou A, Kardara E, Kaltsas S, Doufexis D, Tzovaras A, Mourgela S, Ardavanis A.

Clin Breast Cancer. 2012 Aug;12(4):282-6. doi: 10.1016/j.clbc.2012.04.002. Epub 2012 May 19. No abstract available.

PMID:
22609269
18.

Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature.

Papadimitriou K, Kountourakis P, Morakis E, Vassiliou V, Barbounis V, Ardavanis A.

Case Rep Med. 2012;2012:810428. doi: 10.1155/2012/810428. Epub 2012 Apr 11.

19.

Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.

Tsoukalas N, Tzovaras AA, Tolia M, Kostakis ID, Papakostidi A, Pistamaltzian N, Ardavanis A.

J BUON. 2012 Jan-Mar;17(1):73-8.

PMID:
22517696
20.

Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Talieri M, Zoma M, Devetzi M, Scorilas A, Ardavanis A.

Tumour Biol. 2012 Oct;33(5):1375-83. doi: 10.1007/s13277-012-0385-4. Epub 2012 Apr 3.

PMID:
22477710
21.

Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact.

Talieri M, Devetzi M, Scorilas A, Pappa E, Tsapralis N, Missitzis I, Ardavanis A.

Tumour Biol. 2012 Aug;33(4):1075-84. doi: 10.1007/s13277-012-0347-x. Epub 2012 Feb 21.

PMID:
22351561
22.

Predictors for the development of cholangiocarcinoma and hepatocellular carcinoma: in search for the most accurate biomarker.

Tzovaras AA, Kamposioras K, Ardavanis A.

Arch Med Sci. 2011 Dec 31;7(6):925-7. doi: 10.5114/aoms.2011.26600. Epub 2011 Dec 30. No abstract available.

23.

Barrett's esophagus: treatment or observation of a major precursor factor of esophageal cancer?

Kountourakis P, Papademetriou K, Ardavanis A, Papamichael D.

J BUON. 2011 Jul-Sep;16(3):425-30. Review.

PMID:
22006743
24.

The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias.

Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A.

Adv Hematol. 2012;2012:524308. doi: 10.1155/2012/524308. Epub 2011 Sep 14.

25.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D.

Ann Oncol. 2012 May;23(5):1164-9. doi: 10.1093/annonc/mdr405. Epub 2011 Sep 21.

PMID:
21937705
26.

Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression.

Talieri M, Devetzi M, Scorilas A, Prezas P, Ardavanis A, Apostolaki A, Karameris A.

Anticancer Res. 2011 Sep;31(9):3093-100.

PMID:
21868565
27.

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.

Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2012 Jan;69(1):35-42. doi: 10.1007/s00280-011-1663-3. Epub 2011 May 18.

PMID:
21590447
28.

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.

Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S.

Clin Lung Cancer. 2011 Mar;12(2):100-5. doi: 10.1016/j.cllc.2011.03.004. Epub 2011 Apr 11.

PMID:
21550556
29.

Effective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.

Tzovaras AA, Karagiannis A, Margari C, Barla G, Ardavanis A.

Anticancer Res. 2011 Mar;31(3):1033-7.

PMID:
21498734
30.

Clinical evaluation of PRMT1 gene expression in breast cancer.

Mathioudaki K, Scorilas A, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, Apostolaki A, Talieri M.

Tumour Biol. 2011 Jun;32(3):575-82. doi: 10.1007/s13277-010-0153-2. Epub 2011 Jan 13.

PMID:
21229402
31.

Visual and hearing loss due to colorectal meningeal carcinomatosis: a case-based review.

Kountourakis P, Ardavanis A.

Clin Adv Hematol Oncol. 2010 Aug;8(8):567-8. Review. No abstract available.

PMID:
20966894
32.

Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.

Papadimitriou K, Ardavanis A, Kountourakis P.

J Thorac Dis. 2010 Sep;2(3):160-70. doi: 10.3978/j.issn.2072-1439.2010.02.03.8. Erratum in: J Thorac Dis. 2013 Aug;5(4):E181. Papademetriou, Konstantinos [corrected to Papadimitriou, Konstantinos].

33.

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.

Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA.

Cancer Immunol Immunother. 2010 Dec;59(12):1781-9. doi: 10.1007/s00262-010-0904-3. Epub 2010 Aug 12.

PMID:
20703455
34.

Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.

Kountourakis P, Doufexis D, Maliou S, Karagiannis A, Kardara E, Margari C, Sykoutri D, Tzovaras A, Ardavanis A.

Anticancer Res. 2010 Jul;30(7):2969-71.

PMID:
20683040
35.

Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor.

Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A, Scorilas A.

Tumour Biol. 2010 Oct;31(5):391-9. doi: 10.1007/s13277-010-0047-3. Epub 2010 Jun 1.

PMID:
20514538
36.

Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.

Kountourakis P, Missitzis I, Doufexis D, Zobolas V, Pissakas G, Arnogiannaki N, Maliou S, Sotiropoulou A, Ardavanis A.

J Cancer Res Clin Oncol. 2011 Feb;137(2):221-8. doi: 10.1007/s00432-010-0878-8. Epub 2010 Apr 13.

PMID:
20387073
37.

Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.

Ardavanis A, Kountourakis P, Karagiannis A, Doufexis D, Tzovaras AA, Rigatos G.

Anticancer Res. 2009 Dec;29(12):5211-7.

38.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.

Stathopoulos GP, Ardavanis A, Papakotoulas P, Pectasides D, Papadopoulos G, Antoniou D, Athanasiadis A, Trafalis D, Anagnostopoulos A, Koutantos J, Vaslamatzis M.

Anticancer Drugs. 2010 Feb;21(2):202-5. doi: 10.1097/CAD.0b013e3283350092.

PMID:
20010424
39.

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.

Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group.

Ann Oncol. 2010 Jan;21(1):48-54. doi: 10.1093/annonc/mdp498. Epub 2009 Nov 11.

PMID:
19906761
40.

Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

Orphanos G, Ardavanis A.

Clin Exp Metastasis. 2010;27(1):19-23. doi: 10.1007/s10585-009-9298-z. Epub 2009 Nov 11. Review.

PMID:
19904616
41.

Paraneoplastic cerebellar degeneration in a patient with pseudomyxoma peritonei and breast cancer: case report and literature review.

Ardavanis A, Sykoutri D, Kountourakis P, Doufexis D, Korkolis D, Tzerbini H, Skarlatos I, Mosa E, Rigatos G.

In Vivo. 2009 Sep-Oct;23(5):835-8.

42.

Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study.

Ardavanis A, Doufexis D, Kountourakis P, Malliou S, Karagiannis A, Kardara E, Sykoutri D, Charalampia M, Rigatos G.

BMC Cancer. 2009 Sep 23;9:338. doi: 10.1186/1471-2407-9-338.

43.

Cardiotoxicity induced by tyrosine kinase inhibitors.

Orphanos GS, Ioannidis GN, Ardavanis AG.

Acta Oncol. 2009;48(7):964-70. doi: 10.1080/02841860903229124. Review.

PMID:
19734999
44.

A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Orphanos G, Alexopoulos A, Malliou S, Ioannidis G, Ardavanis A, Kandylis C, Stavrakakis J, Rigatos G.

J Cancer Res Clin Oncol. 2010 Jan;136(1):115-21. doi: 10.1007/s00432-009-0642-0.

PMID:
19672628
45.

Leptomeningeal carcinomatosis presenting as bilateral sensorineural deafness and unilateral facial palsy.

Mourgela S, Sakellaropoulos A, Ardavanis A.

J BUON. 2009 Apr-Jun;14(2):317-9.

PMID:
19650186
46.

Colon cancer and protein arginine methyltransferase 1 gene expression.

Papadokostopoulou A, Mathioudaki K, Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E, Talieri M.

Anticancer Res. 2009 Apr;29(4):1361-6.

47.

Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer.

Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, Diamandis EP, Xynopoulos D, Ardavanis A, Arnogiannaki N, Scorilas A.

Thromb Haemost. 2009 Apr;101(4):741-7.

PMID:
19350120
48.

Systemic sclerosis associated with rectal cancer. Case report and a brief review of the literature.

Orphanos G, Ardavanis A, Charalambous P, Stavrakakis J, Rigatos G.

In Vivo. 2008 Nov-Dec;22(6):825-9.

49.

Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.

Ardavanis A, Kountourakis P, Mantzaris I, Malliou S, Doufexis D, Sykoutri D, Fragos I, Rigatos G.

Anticancer Res. 2008 Sep-Oct;28(5B):3087-92.

50.

Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.

Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A, Kardara E, Frangos I, Koumna S, Baziotis N, Scorilas A, Ardavanis A.

J BUON. 2008 Jul-Sep;13(3):409-13.

PMID:
18979558

Supplemental Content

Loading ...
Support Center